Fred Guerard, PharmD, CEO of Opthea, outlines the clinical development of sozinibercept in combination with standard-of-care anti-VEGF-A therapies, which has the potential to deliver superior visual outcomes in patients with wet age-related macular degeneration (wet AMD).
Sozinibercept Offers Hope for Better Vision to Wet AMD Patients
Sponsored By Opthea
11/14/2024
2 min read
